US-based Illumina has debuted an updated version of its VeriSeq NIPT Analysis Software for clinical laboratories in the European Union (EU), to perform optimised data analysis for non-invasive prenatal testing (NIPT).

The new version of the analysis software is equipped with a new method to process samples and is developed for larger batches of 48 samples, expanding the current 16 samples.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The validated CE-IVD marked analysis software analyses sequencing data for use in NIPT by utilising a whole-genome sequencing (WGS)-based method, which involves analysis of trisomy 13, 18, 21, sex chromosome aneuploidies.

"With this software, Illumina is enabling more clinical laboratories to implement NIPT testing efficiently and affordably in-house."

Illumina Reproductive and Genetic Health vice-president and general manager Jeff Hawkins said: “The update to the VeriSeq NIPT Analysis Software is another important milestone towards providing a more complete high-quality NIPT solution to our laboratory partners in the EU.

“With this software, Illumina is enabling more clinical laboratories to implement NIPT testing efficiently and affordably in-house, increasing overall workflow efficiency and reducing the costs of testing.”

See Also:

The software filters and aligns WGS sequencing reads to a reference genome, prior to using counting-based algorithm to identify over- or under- represented test chromosomes, resulting in a normalised chromosome value (NCV) for the test chromosome.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The firm has applied for CE marking of the upgraded software, which introduces a paired-end sequencing data method.

It identifies and differentes fetal aneuploidy status for chromosomes 21, 18, 13, X and Y through sequencing data analysis generated from cell-free DNA fragments, which are isolated from maternal peripheral whole blood specimens in pregnant women of at least 10 weeks gestation.